Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Connect Biopharma Holdings Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CNTB
Nasdaq
8731
https://www.connectbiopharm.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Connect Biopharma Holdings Ltd
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
- May 7th, 2024 10:30 am
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
- May 2nd, 2024 5:34 pm
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
- Apr 16th, 2024 8:05 pm
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
- Mar 19th, 2024 12:30 pm
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
- Feb 12th, 2024 9:30 pm
Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
- Jan 29th, 2024 11:52 am
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
- Dec 18th, 2023 2:40 pm
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
- Dec 12th, 2023 11:00 am
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
- Dec 11th, 2023 9:05 pm
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
- Nov 30th, 2023 2:45 pm
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
- Nov 28th, 2023 2:40 pm
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
- Nov 21st, 2023 12:32 pm
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
- Nov 21st, 2023 11:03 am
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
- Nov 21st, 2023 11:00 am
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
- Nov 20th, 2023 9:41 pm
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 41% ownership, insiders own 22%
- Nov 9th, 2023 11:07 am
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?
- Nov 6th, 2023 2:40 pm
Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?
- Oct 20th, 2023 1:40 pm
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?
- Sep 15th, 2023 4:00 pm
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
- Sep 12th, 2023 8:15 pm
Scroll